Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
about
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Using the theory of planned behavior to improve treatment adherence in Mexican Americans with schizophreniaCost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled TrialRole of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective.The Promises and Challenges of Ecological Momentary Assessment in Schizophrenia: Development of an Initial Experimental ProtocolTimes to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive DisorderShould we listen and talk more to our patients?Short Text Messages to Encourage Adherence to Medication and Follow-up for People With Psychosis (Mobile.Net): Randomized Controlled Trial in Finland.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Pharmacological treatment of schizophrenia with comorbid substance use disorder.Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in JapanPsychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder.Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders.Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis.Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-term psychosis.
P2860
Q34554423-0F73B492-DBFE-4289-B2DD-1A80EBDEBDFBQ35073474-F99F11AF-B75F-4DE4-B73A-1B56974C1884Q35971060-57AD3B6A-09D7-4425-803A-B7B707FF7E2EQ36059843-87594057-0400-4F18-A8CF-FCF0D2F96F19Q36068636-E7FFF3D0-2000-488E-9E91-06FD06D92F2AQ36137208-67CC5166-11E3-48E9-9A48-BEC52D72C000Q36168916-3A1B0740-3026-4DFB-8DB1-A0D828418C74Q36383958-96B1E2FD-6D7B-43B5-B082-E091C91BEE94Q37136995-C12D6C45-2FFE-4802-A837-AC2B1AEDC22BQ37236159-54C3BF5E-3814-4618-AB94-9DB335828B37Q38373191-E9832F56-F54F-41C7-BC4B-B20D37A9C657Q38473914-9E5DF0FF-8FBB-494E-B819-07E7BFD93449Q38658672-C880EA73-3C98-4CDE-A563-9DF33734D0D4Q40427460-B886DF93-BAEA-4BBD-A667-7AD7D8D65062Q42706295-A09CD670-2E06-4B95-98C0-C6455F245B03Q47785684-9D081E91-05CA-4367-8F9F-425F3A3DD48CQ50527605-952E9797-6C51-4179-8DB3-2F3F5CEF46E7Q50561711-F9680A9A-F6D3-42E7-9825-53FD7339D37FQ55449451-53EB8781-3ECE-4B22-AA54-A4DF01B1447B
P2860
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Time to discontinuation of fir ...... he treatment of schizophrenia.
@en
Time to discontinuation of fir ...... he treatment of schizophrenia.
@nl
type
label
Time to discontinuation of fir ...... he treatment of schizophrenia.
@en
Time to discontinuation of fir ...... he treatment of schizophrenia.
@nl
prefLabel
Time to discontinuation of fir ...... he treatment of schizophrenia.
@en
Time to discontinuation of fir ...... he treatment of schizophrenia.
@nl
P2093
P2860
P1476
Time to discontinuation of fir ...... he treatment of schizophrenia.
@en
P2093
Benjamin Ehrenreich
Clayton H Brown
Deborah R Medoff
Eric P Slade
Joseph Afful
Julie Kreyenbuhl
Lisa B Dixon
P2860
P304
P356
10.1016/J.SCHRES.2011.04.028
P407
P577
2011-05-14T00:00:00Z